NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) and RedShiftBio Combine Proprietary Technology to Create Powerful Biotherapeutic Drug Development Platform
Pressure BioScience (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the worldwide life sciences and other industries, today announced that the combination of PBIO's patented Pressure Cycling Technology ("PCT") with RedShiftBio's proprietary Microfluidic Modulation Spectroscopy ("MMS") has resulted in a powerful new platform for biotherapeutic drug development ("PCT-enhanced MMS"). PBIO believes combining both platforms enables for the rigorous investigation of protein structure and stability in a highly efficient workflow that can be crucial in drug development. Per the release, the collaboration should result in faster development of new drugs…







